A
Actuate Therapeutics, Inc. (ACTU)
NGM – Real vaqt narxi. Valyuta: USD
2.15
-0.12 (-5.29%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.15
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NGM – Real vaqt narxi. Valyuta: USD
2.15
-0.12 (-5.29%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.15
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:10 PM EDT
Actuate Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda saratonni davolash uchun terapiyalarni ishlab chiqadi. Kompaniyaning yetakchi mahsulot nomzodi elraglusib inyektsiyasi bo'lib, bu glikogen sintaza kinaz-3 inhibitore bo'lib, u metastatik oshqozon osti bezi o'simtasini davolash uchun 2-bosqich sinovida. Kompaniya, shuningdek, elraglusibni ishlab chiqadi, u Ewing sarkomasi, shuningdek, metastatik melanoma va kolorektal saratonni o'z ichiga olgan refrakter bolalar malignitelerini davolash uchun 1/2-bosqich sinovida. Kompaniya ilgari Apotheca Therapeutics, Inc. nomi bilan tanilgan va 2015-yil oktyabr oyida Actuate Therapeutics, Inc. nomiga o'zgargan. Actuate Therapeutics, Inc. 2015-yilda ro'yxatga olingan va shtab-kvartirasi Fort Worth, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Alan Kozikowski Ph.D. | Scientific Founder and Advisor |
| Dr. Andrew P. Mazar Ph.D. | Co-Founder & COO |
| Mr. Daniel M. Schmitt | CEO, President & Director |
| Mr. Paul J. Lytle CPA | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-12 | 8-K | actuate_8k.htm |
| 2025-11-28 | 8-K | actuate_8k.htm |
| 2025-11-21 | 8-K | actuate_8k.htm |
| 2025-11-13 | 10-Q | actuate_i10q-093025.htm |
| 2025-09-10 | 8-K | actuate_8k.htm |
| 2025-09-04 | CORRESP | filename1.htm |
| 2025-09-02 | CORRESP | filename1.htm |
| 2025-08-18 | DRS | filename1.htm |
| 2025-08-14 | 10-Q | actuate_i10q-063025.htm |
| 2025-07-31 | CORRESP | filename1.htm |